Filing Details

Accession Number:
0001144204-16-074239
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-01-05 21:00:50
Reporting Period:
2016-01-01
Filing Date:
2016-01-05
Accepted Time:
2016-01-05 21:00:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1353128 Gayle Barbara Duncan C/O Intercept Pharmaceuticals, Inc.
450 W. 15Th Street, Suite 505
New York NY 10011
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-01-01 1,298 $0.00 25,360 No 4 M Direct
Common Stock Disposition 2016-01-04 40 $145.90 25,320 No 4 S Direct
Common Stock Disposition 2016-01-04 428 $145.90 24,892 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2016-01-01 1,298 $0.00 1,298 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.
  2. Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
  3. On November 16, 2012, the reporting person was granted 20,769 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, vested on January 1, 2016, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). All of the shares underlying the RSUs are fully vested as of January 1, 2016.